VRTX Vertex Pharmaceuticals Incorporated

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 10 December 2019 Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene

   - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - Vertex Pharmaceuticals (Europe) Limited today announced that the European

2. 20 November 2019 French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis

   Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS) have approved national reimbursement of ORKAMBI® (lumacaftor/ivacaftor)

3. 19 November 2019 CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

   -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta

4. 18 November 2019 Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

   -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE

5. 13 November 2019 Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines

   -Eligible patients in Wales will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement- Vertex

6. 12 November 2019 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines

   -Eligible patients in Northern Ireland will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement-

7. 07 November 2019 Vertex to Present at the Credit Suisse Healthcare Conference on November 12

   Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET. Management's remarks will be

8. 31 October 2019 Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet

   - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual

9. 31 October 2019 Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis

   - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del

10. 30 October 2019 Vertex Reports Third-Quarter 2019 Financial Results

    - Product revenues of $950 million, a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

11. 24 October 2019 Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines

    -Eligible patients in England will have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor)- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

12. 21 October 2019 Vertex to Announce Third-Quarter 2019 Financial Results on October 30

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and

13. 21 October 2019 FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

    - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del

14. 21 October 2019 Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in

15. 19 October 2019 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are

16. 18 October 2019 Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age

    - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - Vertex Pharmaceuticals (Europe) Limited today announces that the European

17. 01 October 2019 Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company's Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will

18. 30 September 2019 Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

    -Partnership will leverage Ribometrix's discovery platform for up to three therapeutic programs- -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones

19. 12 September 2019 Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

    Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

20. 10 September 2019 Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET. The audio portion of

21. 03 September 2019 Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

    -Semma's unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired